BRIM Biotechnology Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing B… Read more
BRIM Biotechnology Inc. - Asset Resilience Ratio
BRIM Biotechnology Inc. (6885) has an Asset Resilience Ratio of 33.68% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how BRIM Biotechnology Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down BRIM Biotechnology Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$552.35 Million | 33.68% |
| Total Liquid Assets | NT$552.35 Million | 33.68% |
Asset Resilience Insights
- Very High Liquidity: BRIM Biotechnology Inc. maintains exceptional liquid asset reserves at 33.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BRIM Biotechnology Inc. Industry Peers by Asset Resilience Ratio
Compare BRIM Biotechnology Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for BRIM Biotechnology Inc. (2019–2023)
The table below shows the annual Asset Resilience Ratio data for BRIM Biotechnology Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 42.03% | NT$747.63 Million | NT$1.78 Billion | +37.22pp |
| 2021-12-31 | 4.81% | NT$23.84 Million | NT$495.44 Million | -22.43pp |
| 2020-12-31 | 27.24% | NT$86.42 Million | NT$317.28 Million | +7.85pp |
| 2019-12-31 | 19.39% | NT$86.42 Million | NT$445.78 Million | -- |